ClinicalTrials.gg
RecruitingNCT07205432Updated Oct 3, 2025

Phase I Study of XTL6001 Injection in Healthy and Obese Subjects

A Phase 1 interventional study of XTL6001 and Placebo in Weight Management in Adult Patients With Obesity or Overweight, sponsored by Shanghai Xitaili Biomedicine Technology co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Shanghai Xitaili Biomedicine Technology co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 330 studies in Overweight with a site in China — 123 open to participants now, 166 under way, 43 of them phase 3. Overweight · China.

Planned enrollment
180th of 296
80 · median 120
Started
2025
with 65 others
Phase 1
82 of 330
25 open now
Primary completion
2026-04
later than 28 of 165 live
Registered
182nd of 330
by date

Among the 330 studies in Overweight with a site in China, this one is the 180th largest by planned enrollment of the 296 interventional ones that give a count, is one of 66 that started in 2025, is one of 82 in phase 1, reaches primary completion later than 28 of the 165 other live ones, and was the 182nd registered.

Overweight

3,608 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

123 of the 330 studies in Overweight with a site in China are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 330 studies in Overweight with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) and multiple ascending dose (MAD) of XTL6001 injection in healthy and obese adult subjects.

SAD study: Includes 5 dose cohorts, with 40 subjects planned for enrollment. MAD study Includes 2 dose cohorts, with 30 subjects planned for enrollment.

03

Conditions studied

  • Weight Management in Adult Patients With Obesity or Overweight

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria for Subjects in SAD part:

  1. Age ≥ 18 and \< 65 years at screening.
  2. (BMI) ≥ 18.5 kg/m² and \< 28.0 kg/m² at screening.
  3. Body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females at screening.
  4. Signed form prior to the trial, with full understanding of the study objectives, procedures, and potential adverse reactions.

Inclusion Criteria for Subjects in MAD part:

  1. Age ≥ 18 and \< 65 years at screening.
  2. BMI ≥ 18.5 kg/m2且 \< 40.0kg/m².
  3. Body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females at screening.
  4. Stable body weight (fluctuation \< 5%) for at least 3 months prior to screening.
  5. Signed informed consent form prior to the trial, with full understanding of the study objectives, procedures, and potential adverse reactions.

Exclusion Criteria:

Exclusion Criteria for Subjects in SAD part:

  1. History of type 1 or type 2 diabetes mellitus, or > 6.5% or fasting plasma glucose > 7.0 mmol/L at screening.
  2. gastric emptying disorders, chronic use of medications directly affecting gastrointestinal motility, severe chronic gastrointestinal diseases, or prior gastrointestinal surgery.
  3. History of acute or chronic pancreatitis.
  4. Symptomatic gallbladder disease.
  5. within 5 years prior to screening (except adequately treated non-melanoma skin cancer).
  6. Personal/family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2A/2B (MEN 2A/2B).
  7. Female subjects with positive pregnancy test or lactation.

Exclusion Criteria for Subjects in MAD part:

  1. History of type 1 or type 2 diabetes mellitus, or HbA1c > 6.5% or fasting plasma glucose > 7.0 mmol/L at screening.
  2. UnderlyingCushing's syndrome, hypothyroidism, PCOS,.
  3. Clinically significant gastric emptying disorders, chronic use of medications directly affecting gastrointestinal motility, severe chronic gastrointestinal diseases, or gastrointestinal surgeries that may compromise safety or data interpretation.
  4. History of acute or chronic pancreatitis.
  5. Symptomatic gallbladder disease.
  6. Malignancy within 5 years prior to screening (except adequately treated non-melanoma skin cancer).
  7. Personal/family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2A/2B (MEN 2A/2B).
  8. Female subjects with positive pregnancy test or lactation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    XTL6001

    Interventional: The SAD study involves single administration of XLT6001, while the MAD study involves administration of XLT6001 for no more than 4 weeks.

    Drug: XTL6001

  • Placebo comparator
    Placebo

    Placebo: The SAD study involves single administration of Placebo, while the MAD study involves administration of Placebo for no more than 4 weeks.

    Drug: Placebo

Interventions

  • DrugXTL6001

    XTL6001 is a triple-target Glucagon-like peptide-1 receptor (GLP-1R) relevant agonist, intending to manage overweight/obesity and other metabolic diseases

  • DrugPlacebo

    This intervention contains no active ingredients

06

What researchers measure

Primary outcomes

  1. Incidence and severity of AEs (Adverse Events) and SAEs (Serious Adverse Events)

    Time frame: SAD: up to Day 8 MAD: up to Day 57

Secondary outcomes

  1. The maximum plasma concentration (Cmax) of XTL6001

    Cmax - Maximum plasma concentration

    Time frame: Within 1 hour before each weekly dosing, and at 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours after the first and last dose administration of the target dose level.

  2. Tmax of XTL6001

    The time to maximum concentration (Tmax) of XTL6001

    Time frame: Within 1 hour before each weekly dosing, and at 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours after the first and last dose administration of the target dose level.

  3. Elimination half-life (T1/2) of XTL6001

    t1/2 - Elimination half-life

    Time frame: Within 1 hour before each weekly dosing, and at 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours after the first and last dose administration of the target dose level.

  4. Area under the plasma concentration-time curve during one dosing interval (AUC) 0-tau of XTL6001

    AUC0-tau - Area under the plasma concentration-time curve during one dosing interval

    Time frame: Within 1 hour before each weekly dosing, and at 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours after the first and last dose administration of the target dose level.

  5. AUC0-t of XTL6001

    AUC0-t - Area under the plasma concentration-time curve from time zero to the last measurable concentration

    Time frame: Within 1 hour before each weekly dosing, and at 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours after the first and last dose administration of the target dose level.

  6. Body weight

    Body weight

    Time frame: MAD: up to Day57

  7. Body mass index (BMI)

    Body mass index

    Time frame: MAD: up to Day57

  8. Waist circumference

    waist circumference

    Time frame: MAD: up to Day57

  9. Waist-to-hip ratio

    waist-to-hip ratio

    Time frame: MAD: up to Day57

  10. Blood lipids

    Total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein A1 and apolipoprotein B

    Time frame: MAD: up to Day57

  11. Blood glucose

    Blood glucose

    Time frame: MAD: up to Day57

  12. Insulin

    Insulin

    Time frame: MAD: up to Day57

  13. Uric acid

    Uric acid

    Time frame: MAD: up to Day57

  14. Anti-drug antibodies (ADA)

    Incidence of anti-drug antibodies (ADA)

    Time frame: MAD: up to Day57

  15. ADA

    Time to ADA positivity

    Time frame: MAD: up to D57

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Apr 2026, 10 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 10 months is above that.

Counting every sponsor, half of 231 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Oct 3, 2025
StartActual
Jun 13, 2025
Primary completionEst.
Apr 2026
CompletionEst.
Apr 2026
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07205432
Lead sponsor
Shanghai Xitaili Biomedicine Technology co., Ltd.
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Jun 13, 2025
Primary completion
Apr 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Oct 3, 2025

Study contacts

Xiao Hua Hao, Ph.D. in Medicine
Contact
xiaohualuck@sina.com
010-63926883

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion